

Joan Montero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6794204/publications.pdf>

Version: 2024-02-01

39
papers

2,864
citations

304368

22
h-index

377514

34
g-index

42
all docs

42
docs citations

42
times ranked

6401
citing authors

#	ARTICLE	IF	CITATIONS
1	Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics. <i>Cancer Discovery</i> , 2022, 12, 1217-1232.	7.7	16
2	MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment. <i>Cell Death Discovery</i> , 2022, 8, 172.	2.0	4
3	Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 851825.	2.0	4
4	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i91-i92.	0.6	0
5	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
6	ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. <i>Cells</i> , 2021, 10, 1659.	1.8	16
7	Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3K± Inhibitor Resistance Mechanisms and Drug Combinations. <i>Cancer Research</i> , 2021, 81, 4603-4617.	0.4	13
8	MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 695225.	1.8	4
9	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , 2021, 12, 977.	2.7	33
10	A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 761-763.	3.2	8
11	PI3K± inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.	2.5	23
12	Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. <i>Cell Death and Disease</i> , 2020, 11, 634.	2.7	17
13	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2281-2293.	1.5	29
14	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019, 10, 5157.	5.8	46
15	Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1027-1032.	3.3	64
16	p21: One protein to rule cell fate. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	2
17	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5005-5019.	3.9	59
18	The attack of the "seeding" clones. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0

#	ARTICLE	IF	CITATIONS
19	Dual oncogene excision is greater than the sum of its parts. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0
20	Modeling endometrial disease using organoids. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0
21	Ingestible macromolecule injectors. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0
22	A new hope for neuroblastoma treatment?. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0
23	Why do BCL-2 inhibitors work and where should we use them in the clinic?. <i>Cell Death and Differentiation</i> , 2018, 25, 56-64.	5.0	251
24	The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading. <i>Redox Biology</i> , 2018, 14, 164-177.	3.9	59
25	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	7.7	164
26	Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	155
27	Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. <i>Oncotarget</i> , 2017, 8, 16220-16232.	0.8	22
28	Dynamic BH3 profiling-poking cancer cells with a stick. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1040144.	0.3	24
29	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
30	iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. <i>Biological Chemistry</i> , 2016, 397, 671-678.	1.2	94
31	Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy. <i>Cell</i> , 2015, 160, 977-989.	13.5	295
32	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 29-41.	7.7	95
33	Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs). <i>Blood</i> , 2014, 124, 3713-3713.	0.6	1
34	BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response. <i>Molecular Cell</i> , 2013, 51, 751-765.	4.5	200
35	<sc>KPT</sc>â€³30 inhibitor of <sc>CRM</sc>1 (<sc>XPO</sc>1)â€mediated nuclear export has selective antiâ€leukaemic activity in preclinical models of <sc>T</sc>â€cell acute lymphoblastic leukaemia and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 117-127.	1.2	149
36	p53 regulates a non-apoptotic death induced by ROS. <i>Cell Death and Differentiation</i> , 2013, 20, 1465-1474.	5.0	115

#	ARTICLE	IF	CITATIONS
37	Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 934-947.	7.7	255
38	Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2010, 1797, 1217-1224.	0.5	90
39	Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 5246-5256.	0.4	219